Dark Spots & Melasma Guide: Pigmentation, Treatment & Safety

Quick answer: identify the pigment problem before trying to fade it

Dark marks after acne, recurrent facial melasma and a single changing spot are not interchangeable diagnoses. The useful starting sequence is to identify the cause, control ongoing inflammation or irritation, protect against relevant light exposure and then consider a tolerable treatment. A stronger peel is not automatically a better solution, particularly when irritation itself creates more pigmentation.^{1, 2, 3}

For melasma and post-inflammatory marks, AAD guidance emphasizes sun protection, including a tinted sunscreen with iron oxide for visible-light protection. Prescription options can help selected people, but no cream is a dependable permanent cure for every form of discoloration. An unfamiliar lesion that changes, bleeds or does not heal needs assessment rather than a lightening experiment.

1. Separate post-inflammatory marks, melasma and other lesions

Post-inflammatory hyperpigmentation can follow acne, eczema, psoriasis, burns, bites or other injury. It can also follow an irritating skin or hair product. If inflammation continues, new marks may develop while older ones fade; the problem may be ongoing injury, not a missing brightening ingredient. Treating the underlying condition is therefore part of pigment management.¹

Melasma usually presents as bilateral, blotchy brown facial pigmentation. Genetics, ultraviolet and visible light, pregnancy, hormonal medicines and other factors can contribute. Its distribution and course can suggest the diagnosis, but a photograph or a color chart cannot establish it reliably. DermNet lists several other pigment disorders that can resemble it.³

On smaller screens, scroll the table sideways.

A flat pigment mark also differs from an indentation or raised scar. A study showing improvement in skin color does not establish reconstruction of scar tissue. For active breakouts, use the Acne & Blemish Care Guide; controlling new lesions can be more important than adding a spot-fading serum.

2. Build a useful history without self-diagnosing hormone disease

Record when the discoloration appeared, whether it followed inflammation, how it changes with seasons and which products or medicines were introduced. Include pregnancy, contraception, procedures and occupational exposures where relevant. Do not stop a prescribed medicine or contraception simply because a general article lists it as a possible contributor. Ask the prescribing clinician to assess the trade-off.^{1, 3}

Dermatologists often diagnose melasma clinically and may use a Wood lamp or dermatoscope. Occasionally another test, including biopsy, is needed to exclude a different condition. These are tools used in context; a home light or a phone camera is not a substitute for that assessment.^{2, 3}

Skin tone changes the practical decision, not the value of normal skin

The aim is to address unwanted acquired discoloration or the underlying condition—not to treat someone’s natural skin color as a defect. Darker skin tones can be particularly vulnerable to post-inflammatory pigment changes, so tolerability is a meaningful outcome. Aggressively chasing a lighter shade can undermine the original goal by provoking additional inflammation.¹

State what you actually want to improve: fewer new marks, less contrast, less recurrence or less distress. Those outcomes may call for different actions. Choosing not to treat a confirmed benign cosmetic concern is also reasonable; camouflage makeup is an option rather than an admission that treatment failed.²

3. Treat light protection as part of pigment care

Broad-spectrum sunscreen addresses ultraviolet exposure; iron oxide in tinted formulations can help address visible light, which can worsen melasma, especially in darker skin tones. AAD guidance recommends a tolerable tinted product with SPF 30 or higher, broad-spectrum protection and suitable water resistance. Tint alone does not establish an SPF or prove that every pigmented cosmetic has the same protective effect.^{1, 4}

Iron oxide can appear in the inactive ingredient list in US sunscreen labeling because UV-filtering ingredients are classified separately. Look at both the protective label and the ingredient list rather than assuming a cosmetic shade provides tested ultraviolet protection. The shade and feel should allow adequate use rather than encouraging an almost invisible dab.¹

Shade, a broad-brimmed hat and practical coverage remain useful. Reapply according to the sunscreen’s directions and outdoor activity. For amounts, water resistance and application detail, see the Sun Protection & Photoaging Guide. This cluster does not repeat a complete sunscreen protocol.

Visible-light advice does not mean ordinary indoor lighting is equivalent to midday outdoor sunlight, or that every reader must avoid all screens. The cited guidance concerns a pigment-management plan, not a validated universal screen-exposure threshold. Avoid turning prevention into an unsupported fear of everyday environments.

4. Compare topical options without assuming equivalence

AAD patient education describes hydroquinone, retinoid-based combinations and other options such as azelaic acid, kojic acid and vitamin C for selected pigment concerns. A clinician may choose treatment based on diagnosis, tolerance, skin tone and history. An ingredient’s presence does not establish that all concentrations, derivatives or finished formulas perform equally.^{1, 2}

On smaller screens, scroll the table sideways.

A prescription combination and a cosmetic “brightening complex” are different evidence questions. Ask what exact preparation was studied and against what comparison. A multi-ingredient trial may support that complete formulation without showing which ingredient produced the effect. Avoid treating several ingredient studies as if they tested the blend in your bottle.

Why irritation matters more than intensity

Burning and stinging are not reliable signals of pigment being removed. AAD melasma advice recommends gentle, fragrance-free products and notes that irritation can darken spots. If a regimen repeatedly inflames the skin, review it rather than adding another exfoliant or increasing the frequency.⁴

Supportive cleansing and moisturization belong here as enablers of tolerability, not as a claim that a moisturizer treats all melasma. The Skin Barrier Guide explains those decisions in more detail.

5. Understand why some treatments require medical supervision

Hydroquinone can be useful in a clinician-selected plan, but FDA reports include rashes, swelling and ochronosis, a potentially permanent discoloration. US rules distinguish prescription treatment from unapproved OTC skin-lightening sales. Do not translate a warning about unsupervised sales into either “all hydroquinone is forbidden” or “prescription means harmless.”^{2, 5}

A corticosteroid in an established combination serves a defined purpose within a defined regimen. Long-term unsupervised use of an unidentified steroid-lightening cream is different. AAD warns that hidden steroids in some products can cause acne-like eruptions, fragile skin and discoloration. If you have used a product of uncertain composition, bring it to an appointment rather than layering another corrective cream over the problem.¹

Tranexamic acid is not a beauty supplement

For difficult melasma, a dermatologist may discuss tranexamic acid, including oral treatment. AAD highlights the need to disclose a history of blood clots before prescribing. The decision requires a medical risk assessment; this guide does not recommend a dose, online purchase or self-screening checklist that would establish safety.²

Oral and topical routes are not interchangeable. Evidence about one route, selected participants or an adjunctive regimen cannot establish that a differently formulated serum or capsule has the same benefit–risk profile. If a clinic offers treatment, ask what diagnosis and evidence support the recommendation and how adverse effects will be handled.

6. A procedure can improve pigment—or worsen it

Chemical peels, laser and light treatments, and other procedures may be considered in selected cases. DermNet cautions that procedures can worsen melasma or cause post-inflammatory hyperpigmentation; relapse and treatment resistance are concerns. AAD describes procedures as possible additions to individualized care rather than one universally best treatment.^{2, 3}

Ask about experience with your skin tone and the exact diagnosis, the device or peel protocol, realistic duration of benefit, downtime, pigment worsening and management of complications. An impressive before-and-after photograph does not show the full risk, other treatments used or how often results lasted.

Do not attempt a strong home peel or needle the skin to accelerate pigment removal. A professional study does not validate a consumer device, an improvised acid strength or delivery of untested products through injured skin. Active dermatitis and uncertain lesions should be assessed before considering cosmetic injury.

Cost is also part of informed choice. Discuss the whole course, maintenance and possible repeated sessions—not only the introductory price. A more expensive option is not automatically more effective, and a recommendation should include an option to postpone or decline treatment.

7. Set a timeline that reflects the diagnosis

AAD notes that relatively superficial post-inflammatory marks can fade over 6–12 months once the cause stops, whereas deeper pigment can take years. That is context, not a personal countdown. The same source emphasizes identifying and stopping the trigger. A month of ongoing irritation cannot be interpreted as a clean trial of spontaneous fading.¹

For melasma, AAD patient education describes results often taking 3–12 months and sometimes longer. DermNet emphasizes chronicity and recurrence with light exposure. These sources do not support a permanent-cure guarantee, a seven-day transformation or the assumption that relapse proves nothing ever helped.^{2, 3}

On smaller screens, scroll the table sideways.

If photos are useful, use similar lighting, positioning and no filters. Track new inflammation and tolerability as well as color. A phone’s changing white balance can create an apparent improvement or worsening that is not a dependable biological measurement.

8. Screen safety before introducing a fading product

Mercury-containing skin-lightening products pose systemic health risks and are banned for this use in the United States. FDA notes that mercury can appear under names such as calomel, mercurous chloride, mercurio or Hg, and that illegal products may omit it from the label. A polished label or the word “herbal” cannot rule out an undeclared ingredient.⁵

Avoid unidentified or decanted lightening mixtures, and never apply household bleach to treat pigmentation. Keep packaging and ingredient information when asking for advice. FDA’s advice and legal statements here are US-specific; check local rules rather than assuming every country uses the same sales classification.^{1, 5}

Pregnancy and medicines

Melasma can arise during pregnancy, but that does not make every melasma treatment suitable in pregnancy. Discuss active treatments with the obstetric clinician or dermatologist. Do not self-start a retinoid or an oral pigment medicine, and do not stop prescribed contraception or another medicine solely to test an internet theory about the discoloration.

Do not fade an undiagnosed lesion

Arrange assessment for a new or changing pigmented lesion, bleeding, persistent ulceration or a spot that looks unlike the others. A skin-lightening response would not prove that a lesion was harmless. Rapidly spreading pain, extensive blistering or systemic illness also deserves prompt care; trouble breathing or swallowing after a product requires emergency help.

9. Make the next decision smaller and clearer

• Define the concern: post-inflammatory marks, suspected melasma or an uncertain lesion.
• Identify ongoing triggers: acne, dermatitis, friction, light exposure, products and relevant medicines.
• Choose proportionate protection: usable sunscreen, shade and coverage, including visible-light considerations where relevant.
• Review treatment suitability: exact formula, pregnancy, adverse effects, cost and access.
• Set an outcome: fewer new marks, less contrast, less recurrence or improved comfort.
• Plan the review: when to reassess and which changes need earlier medical attention.

This is an editorial decision aid, not a diagnosis or validated severity score. A good result may be a simpler routine and fewer new lesions, not the complete disappearance of every color difference. For the broader framework, return to the Beauty & Personal Care Guide.

Common questions

Is every dark spot melasma?

No. Marks after inflammation, sun-related lesions, medication effects and other conditions can look similar. An uncertain or changing lesion needs examination rather than an assumed melasma diagnosis.^{2, 3}

Does tinted makeup replace sunscreen?

Tint alone does not establish tested UV protection or adequate visible-light protection. Use an appropriately labeled sunscreen and a tolerable protection plan.^{1, 4}

Will peeling make marks fade faster?

Not necessarily. Irritation can produce more pigmentation, and procedures carry diagnosis- and skin-tone-specific risks. More visible peeling is not a reliable benefit measure.^{3, 4}

Can I buy hydroquinone over the counter?

In the United States it is not approved for OTC skin-lightening sale, although prescription treatment is available. Local rules elsewhere differ.⁵

Can melasma come back after successful treatment?

Yes. Relapse is part of the condition’s course for many people. Maintenance and light protection matter, and a recurrence is not a reason to improvise stronger treatment.³

Research method and limitations

This focused adult guide uses AAD patient education, DermNet clinical education and FDA consumer safety information, checked October 27, 2026. It is not a systematic review, independent trial reanalysis or brand comparison. Clinical overviews inform the treatment map; they do not establish a precise comparative ranking of every topical or procedure.

Timelines are attributed to institutional guidance and presented as context rather than guarantees. No product was laboratory-tested, no device was independently evaluated and no medical reviewer was engaged for this article. US regulatory statements are identified as such. Practical worksheets and monitoring suggestions are editorial applications, not validated protocols.

See our Methodology and Sources Policy. Report a correction with the specific claim and source.

Sources and further reading

1. American Academy of Dermatology. How to fade dark spots in darker skin tones. Triggers, post-inflammatory pigmentation, protection and timelines.
2. AAD. Melasma: Diagnosis and treatment. Individualized treatment, supervision and expected course.
3. DermNet. Melasma. Clinical distinctions, relapse and procedural risk; minor update December 2025.
4. AAD. Melasma: Self-care. Visible light, tinted sunscreen and irritation.
5. US Food and Drug Administration. Skin Product Safety. US hydroquinone and mercury sales and safety context.